Promising Biomarkers for Early Detection of Prostate Cancer Risk Identified

byColleen Fleisson August 18, 2023A cell metabolism process observed in males who have diabetes and metastatic prostate cancer holds the potential for future advancements in testing and tr

Updated on: December 19,2023 26

Promising Biomarkers for Early Detection of Prostate Cancer Risk Identified

byColleen Fleisson August 18, 2023A cell metabolism process observed in males who have diabetes and metastatic prostate cancer holds the potential for future advancements in testing and tr

Updated on:December 19,2023 26

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on: December 26,2023 8

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on:December 26,2023 8

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on: January 04,2024 9

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on:January 04,2024 9

Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on: December 22,2023 19

Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on:December 22,2023 19

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on: December 21,2023 9

Survival rates high for children, teens with melanoma

by Lori SolomonSurvival rates for children and adolescents with melanomas are high, according to a study published online Dec. 9 in theJournal of the American Academy of Dermatology.Mary-Ann El

Updated on:December 21,2023 9

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on: December 19,2023 12

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on:December 19,2023 12

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on: December 17,2023 10

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

by Impact Journals LLCEvaluation of the toxicity of MK256 in vivo. Credit:Oncotarget(2022). DOI: 10.18632/oncotarget.28305A new research paper titled "MK256 is a novel CDK8 inhibitor

Updated on:December 17,2023 10

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on: October 30,2023 6

Lung cancer screening guidelines perpetuate racial disparities, study finds

Lung cancer screening guidelines perpetuate racial disparities, study findsby Krista Conger,Stanford UniversityRacial Disparities in the Eligibility-Incidence (E-I) Ratio Through the US Preventi

Updated on:October 30,2023 6

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on: October 11,2023 56

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on:October 11,2023 56

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on: December 19,2023 10

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on:December 19,2023 10

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on: October 12,2023 26

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on:October 12,2023 26

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on: December 18,2023 13

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on:December 18,2023 13